Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease

Objective Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression. Design Retrospective analysis of a case series from a longitudinal, observational study. Participants Two hundred forty-n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology (Rochester, Minn.) Minn.), 2012-12, Vol.119 (12), p.2622-2630
Hauptverfasser: Toy, Brian C., BS, Agrón, Elvira, MA, Nigam, Divya, BS, Chew, Emily Y., MD, Wong, Wai T., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2630
container_issue 12
container_start_page 2622
container_title Ophthalmology (Rochester, Minn.)
container_volume 119
creator Toy, Brian C., BS
Agrón, Elvira, MA
Nigam, Divya, BS
Chew, Emily Y., MD
Wong, Wai T., MD, PhD
description Objective Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression. Design Retrospective analysis of a case series from a longitudinal, observational study. Participants Two hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up. Methods Standardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease. Main Outcome Measures Measures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index). Results Most participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2±4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1±0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration. Conclusions Patients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment. Financial Disclosure(s) The author(s) have no propr
doi_str_mv 10.1016/j.ophtha.2012.06.026
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S016164201200557X</els_id><sourcerecordid>1222234296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-9ff8b737b767711a96d4aba4c44f475f03887aeeeeae9acd23974e364e23d2743</originalsourceid><addsrcrecordid>eNqFkktv1DAQxyMEotvCN0AoFyQuCX7F3lyQqkJZpJUq8RI3a-JMul4Se7GTlfbb1-ku5XFhDrZs_-bl_2TZC0pKSqh8sy39bjNuoGSEspLIkjD5KFvQStSFUJQ_zhYJo4UUjJxl5zFuCSFScvE0O2OsJlIptsjc2rtbO06tddDnl2k5RBtz3-WfcLy_W-EACfFND3H0A4x-BsC1-TcbpwRcT86M1rvcuvzGTD2EfJ9OK7vbYV-srWthyt_ZiBDxWfakgz7i89N-kX29fv_lalWsbz58vLpcF6YSy7Gou27ZKK4alaqkFGrZCmhAGCE6oaqO8OVSASYDrMG0jNdKIJcCGW-ZEvwie3uMu5uaAVuDbgzQ612wA4SD9mD13y_ObvSt32teESE5SQFenwIE_3PCOOrBRoN9Dw79FDVlybhgtUyoOKIm-BgDdg9pKNGzVHqrj1LpWSpNpE5SJbeXf5b44PRLmwS8OgEQDfRdAGds_M1JKWt-X-qpV0wfurcYdDQWncHWBjSjbr39XyX_BjC9dTbl_IEHjFs_hTQIqWcdk4_-PI_VPFWUEVJV6ju_A_w-y48</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1222234296</pqid></control><display><type>article</type><title>Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Toy, Brian C., BS ; Agrón, Elvira, MA ; Nigam, Divya, BS ; Chew, Emily Y., MD ; Wong, Wai T., MD, PhD</creator><creatorcontrib>Toy, Brian C., BS ; Agrón, Elvira, MA ; Nigam, Divya, BS ; Chew, Emily Y., MD ; Wong, Wai T., MD, PhD</creatorcontrib><description>Objective Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression. Design Retrospective analysis of a case series from a longitudinal, observational study. Participants Two hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up. Methods Standardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease. Main Outcome Measures Measures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index). Results Most participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2±4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1±0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration. Conclusions Patients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2012.06.026</identifier><identifier>PMID: 22906772</identifier><identifier>CODEN: OPHTDG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Disease Progression ; Female ; Germ-Line Mutation ; Hemangioblastoma - genetics ; Hemangioblastoma - physiopathology ; Humans ; Longitudinal Studies ; Male ; Medical sciences ; Miscellaneous ; Mutation ; Ophthalmology ; Retinal Neoplasms - genetics ; Retinal Neoplasms - physiopathology ; Retrospective Studies ; Visual Acuity - physiology ; von Hippel-Lindau Disease - genetics ; von Hippel-Lindau Disease - physiopathology ; Von Hippel-Lindau Tumor Suppressor Protein - genetics</subject><ispartof>Ophthalmology (Rochester, Minn.), 2012-12, Vol.119 (12), p.2622-2630</ispartof><rights>American Academy of Ophthalmology</rights><rights>2012 American Academy of Ophthalmology</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><rights>2012 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-9ff8b737b767711a96d4aba4c44f475f03887aeeeeae9acd23974e364e23d2743</citedby><cites>FETCH-LOGICAL-c548t-9ff8b737b767711a96d4aba4c44f475f03887aeeeeae9acd23974e364e23d2743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S016164201200557X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26669330$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22906772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toy, Brian C., BS</creatorcontrib><creatorcontrib>Agrón, Elvira, MA</creatorcontrib><creatorcontrib>Nigam, Divya, BS</creatorcontrib><creatorcontrib>Chew, Emily Y., MD</creatorcontrib><creatorcontrib>Wong, Wai T., MD, PhD</creatorcontrib><title>Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Objective Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression. Design Retrospective analysis of a case series from a longitudinal, observational study. Participants Two hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up. Methods Standardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease. Main Outcome Measures Measures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index). Results Most participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2±4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1±0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration. Conclusions Patients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Germ-Line Mutation</subject><subject>Hemangioblastoma - genetics</subject><subject>Hemangioblastoma - physiopathology</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Mutation</subject><subject>Ophthalmology</subject><subject>Retinal Neoplasms - genetics</subject><subject>Retinal Neoplasms - physiopathology</subject><subject>Retrospective Studies</subject><subject>Visual Acuity - physiology</subject><subject>von Hippel-Lindau Disease - genetics</subject><subject>von Hippel-Lindau Disease - physiopathology</subject><subject>Von Hippel-Lindau Tumor Suppressor Protein - genetics</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkktv1DAQxyMEotvCN0AoFyQuCX7F3lyQqkJZpJUq8RI3a-JMul4Se7GTlfbb1-ku5XFhDrZs_-bl_2TZC0pKSqh8sy39bjNuoGSEspLIkjD5KFvQStSFUJQ_zhYJo4UUjJxl5zFuCSFScvE0O2OsJlIptsjc2rtbO06tddDnl2k5RBtz3-WfcLy_W-EACfFND3H0A4x-BsC1-TcbpwRcT86M1rvcuvzGTD2EfJ9OK7vbYV-srWthyt_ZiBDxWfakgz7i89N-kX29fv_lalWsbz58vLpcF6YSy7Gou27ZKK4alaqkFGrZCmhAGCE6oaqO8OVSASYDrMG0jNdKIJcCGW-ZEvwie3uMu5uaAVuDbgzQ612wA4SD9mD13y_ObvSt32teESE5SQFenwIE_3PCOOrBRoN9Dw79FDVlybhgtUyoOKIm-BgDdg9pKNGzVHqrj1LpWSpNpE5SJbeXf5b44PRLmwS8OgEQDfRdAGds_M1JKWt-X-qpV0wfurcYdDQWncHWBjSjbr39XyX_BjC9dTbl_IEHjFs_hTQIqWcdk4_-PI_VPFWUEVJV6ju_A_w-y48</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Toy, Brian C., BS</creator><creator>Agrón, Elvira, MA</creator><creator>Nigam, Divya, BS</creator><creator>Chew, Emily Y., MD</creator><creator>Wong, Wai T., MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121201</creationdate><title>Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease</title><author>Toy, Brian C., BS ; Agrón, Elvira, MA ; Nigam, Divya, BS ; Chew, Emily Y., MD ; Wong, Wai T., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-9ff8b737b767711a96d4aba4c44f475f03887aeeeeae9acd23974e364e23d2743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Germ-Line Mutation</topic><topic>Hemangioblastoma - genetics</topic><topic>Hemangioblastoma - physiopathology</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Mutation</topic><topic>Ophthalmology</topic><topic>Retinal Neoplasms - genetics</topic><topic>Retinal Neoplasms - physiopathology</topic><topic>Retrospective Studies</topic><topic>Visual Acuity - physiology</topic><topic>von Hippel-Lindau Disease - genetics</topic><topic>von Hippel-Lindau Disease - physiopathology</topic><topic>Von Hippel-Lindau Tumor Suppressor Protein - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toy, Brian C., BS</creatorcontrib><creatorcontrib>Agrón, Elvira, MA</creatorcontrib><creatorcontrib>Nigam, Divya, BS</creatorcontrib><creatorcontrib>Chew, Emily Y., MD</creatorcontrib><creatorcontrib>Wong, Wai T., MD, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toy, Brian C., BS</au><au>Agrón, Elvira, MA</au><au>Nigam, Divya, BS</au><au>Chew, Emily Y., MD</au><au>Wong, Wai T., MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>119</volume><issue>12</issue><spage>2622</spage><epage>2630</epage><pages>2622-2630</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><coden>OPHTDG</coden><abstract>Objective Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression. Design Retrospective analysis of a case series from a longitudinal, observational study. Participants Two hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up. Methods Standardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease. Main Outcome Measures Measures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index). Results Most participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2±4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1±0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration. Conclusions Patients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22906772</pmid><doi>10.1016/j.ophtha.2012.06.026</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0161-6420
ispartof Ophthalmology (Rochester, Minn.), 2012-12, Vol.119 (12), p.2622-2630
issn 0161-6420
1549-4713
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3504630
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Biological and medical sciences
Disease Progression
Female
Germ-Line Mutation
Hemangioblastoma - genetics
Hemangioblastoma - physiopathology
Humans
Longitudinal Studies
Male
Medical sciences
Miscellaneous
Mutation
Ophthalmology
Retinal Neoplasms - genetics
Retinal Neoplasms - physiopathology
Retrospective Studies
Visual Acuity - physiology
von Hippel-Lindau Disease - genetics
von Hippel-Lindau Disease - physiopathology
Von Hippel-Lindau Tumor Suppressor Protein - genetics
title Longitudinal Analysis of Retinal Hemangioblastomatosis and Visual Function in Ocular von Hippel-Lindau Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A45%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20Analysis%20of%20Retinal%20Hemangioblastomatosis%20and%20Visual%20Function%20in%20Ocular%20von%20Hippel-Lindau%20Disease&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Toy,%20Brian%20C.,%20BS&rft.date=2012-12-01&rft.volume=119&rft.issue=12&rft.spage=2622&rft.epage=2630&rft.pages=2622-2630&rft.issn=0161-6420&rft.eissn=1549-4713&rft.coden=OPHTDG&rft_id=info:doi/10.1016/j.ophtha.2012.06.026&rft_dat=%3Cproquest_pubme%3E1222234296%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1222234296&rft_id=info:pmid/22906772&rft_els_id=1_s2_0_S016164201200557X&rfr_iscdi=true